STORM Therapeutics announces closing of USD $30M Series B financing

Proceeds will advance STORM's potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias Financing will further expand STORM's novel discovery platform to create additional products targeting RNA modification ... Biopharmaceuticals, Venture Capital STORM Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news